D-dimer testing in ischemic stroke and cerebral sinus and venous thrombosis

Seminars in Vascular Medicine

Volumn 5, Issue 4, 2005, Pages 379-386

  Squizzato, Alessandro ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cerebral sinus and venous thrombosis; D dimer; Deep venous thrombosis; Diagnosis; Ischemic stroke; Prognosis

Indexed keywords

D DIMER;

ADULT; AGED; BIOASSAY; CEREBRAL SINUS THROMBOSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; FEMALE; HEADACHE; HEMOSTASIS; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; VEIN THROMBOSIS;

BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MASS SCREENING; PROGNOSIS; SINUS THROMBOSIS, INTRACRANIAL; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 27244459972     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922484     Document Type: Review

References (64)

1. Rylatt DB, Blake AS, Cottis LE, et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983;31:767-778
2. Van der Graaf F, van den Borne H, van der Kolk M, de Wild PJ, Janssen GWT, van Uum AHM. Exclusion of deep venous thrombosis with D-dimer testing. Comparison of 13 D-dimer methods in 99 outpatients suspected of deep venous thrombosis using venography as reference standard. Thromb Haemost 2000;83:191-198
3. Gaffney PJ, Creighton LJ, Callus MJ, Thorpe R. Monoclonal antibodies to cross-linked fibrin degradation products (XL-FDP)-Evolution in a variety of clinical conditions. Br J Haematol 1988;68:91-96
4. World Health Organization. World Health Report 2002. Geneva, Switzerland: WHO; 2002
5. Adams HP Jr, Adams RJ, Brott T, et al. Stroke Council of the American Stoke Association. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056-1083
6. Johnson CJ, Kittner SJ, McCarter RJ, et al. Interrater reliability of an etiologic classification of ischemic stroke. Stroke 1995;26:46-51
7. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526
8. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41
9. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735-2740
10. Feinberg WM, Bruck DC, Ring ME, Corrigan JJ Jr. Hemostatic markers in acute stroke. Stroke 1989;20:592-597
11. Fon EA, Mackey A, Cote R, et al. Hemostatic markers in acute transient ischemic attacks. Stroke 1994;25:282-286
12. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47:1075-1079
13. Cote R, Wolfson C, Solymoss S, et al. Hemostatic markers in patients at risk of cerebral ischemia. Stroke 2000;31:1856-1862
14. Ono N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E. Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke patients. Stroke 1991;22:1369-1373
15. Gaines KJ, Chesney C, Vander Zwaag R, Cape C. Racial difference in coagulation studies in stroke. Neurol Res 1992; 14(Suppl):103-108
16. Kataoka S, Hirose G, Hori A, Shirakawa T, Saigan T. Activation of thrombosis and fibrinolysis following brain infarction. J Neurol Sci 2000;181:82-88
17. Takano K, Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute cardioembolic stroke. Stroke 1991;22: 12-16
18. Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable state following acute ischemic stroke. Stroke 1992; 23:194-198
19. Altes A, Abellan MT, Mateo J, Avila A, Marti-Vilalta JL, Fontcuberta J. Hemostatic disturbances in acute ischemic stroke: a study of 86 patients. Acta Haematol 1995;94: 10-15
20. Ince B, Bayram C, Harmanci H, Ulutin T. Hemostatic markers in ischemic stroke of undetermined etiology. Thromb Res 1999;96:169-174
21. Yamamoto Y, Oiwa K, Hayashi M, Imai K, Nakamura T. Coagulation and fibrinolytic activation in lacunar infarct patients. Rinsho Shinkeigaku 1999;39:1104-1108
22. Yamazaki M, Uchiyama S, Maruyama S. Alterations of haemostatic markers in various subtypes and phases of stroke. Blood Coagul Fibrinolysis 1993;4:707-712
23. Ageno W, Finazzi S, Steidl L, et al. Ischemic subtypes plasma measurement of D-Dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med 2002;162:2589-2593
24. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995;73:527-533
25. Hacke W, Kaste M, Fieschi C, et al. For the ECASS Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study. JAMA 1995;274:1017-1025
26. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Diseases and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587
27. Fassbender K, Dempfle CE, Mielke O, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke 1999;30:2101-2104
28. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25: 1755-1759
29. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT Study: a randomized controlled trial: Stroke Treatment with Ancrod Trial. JAMA 2000;283:2395-2403
30. Pollak VE, Glas Greenwalt P, Olinger CP, Wadhwa NK, Myre SA. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325
31. Dempfle CE, Argiriou S, Kucher K, Muller-Peltzer H, Rubsamen K, Heene DL. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod. Blood 2000;96:2793-2802
32. Hankey G, Warlow C. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457-1463
33. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke: the Framingham Study. Stroke 1982;13:290-296
34. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1994;25:333-337
35. Hart R, Benavente O, McBride R, Pearce L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501
36. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641
37. Ridker PM, Hennekens CH, Cerskus A, Stampfer MH. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90:2236-2240
38. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, tissue plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998;79:129-133
39. Lowe GDO, Yarnell JWG, Rumley A, Baiton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001;21:603-610
40. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99: 2517-2522
41. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997;17:3321-3325
42. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke: association with stroke type, severity, and outcome. Stroke 1996;27: 1296-1300
43. Lip GYH, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis 2002;13:339-347
44. Di Napoli M, Papa F. For the Villa Fini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002;33:1763-1771
45. Bruno A, McConnell JP, Cohen SN, et al. Plasma thrombosis markers following cerebral infarction in African Americans. Thromb Res 2005;115:73-77
46. Barber M, Langhorne P, Rumley A, Lowe GDO, Stott DJ. Hemostatic function and progressing ischemic stroke. D-dimer predicts early clinical progression. Stroke 2004;35: 1421-1425
47. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke-back ground and study protocol. Stroke 1985;16:885-890
48. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Intraobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607
49. Wade D. Measurement in Neurological Rehabilitation. 1st ed. Oxford/New York/Tokyo: Oxford University Press; 1992
50. Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci 2005;12:429-434
51. Stam J. Cerebral venous and sinus thrombosis: incidence and causes. Adv Neurol 2003;92:225-232
52. Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis-a review of 38 cases. Stroke 1985;16:199-213
53. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005;352:1791-1798
54. Stam J. The treatment of cerebral venous sinus thrombosis. Adv Neurol 2003;92:233-240
55. Wildberger JE, Mull M, Kilbinger M, Schon S, Vorwerk D. Cerebral sinus thrombosis: rapid test diagnosis by demonstration of increased plasma D-dimer levels (SimpliRED) [in German]. Rofo 1997;167:527-529
56. Talbot K, Wright M, Keeling D. Normal d-dimer levels do not exclude the diagnosis of cerebral venous sinus thrombosis. J Neurol 2002;249:1603-1604
57. Tardy B, Tardy-Poncet B, Viallon A, et al. D-dimer levels in patients with suspected acute cerebral venous thrombosis. Am J Med 2002;113:238-241
58. Lalive PH, de Moerloose P, Lovblad K, Sarasin FP, Mermillod B, Sztajzel R. Is measurement of D-dimer useful in the diagnosis of cerebral venous thrombosis? Neurology 2003;61:1057-1060
59. Kosinski CM, Mull M, Schwarz M, et al. Do normal D-dimer levels reliably exclude cerebral sinus thrombosis? Stroke 2004;35:2820-2825
60. Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc 1997;72:297-300
61. Stein PD, HuU RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004;140:589-602
62. Harvey RL, Roth EJ, Yarnold PR, Durham JR, Green D. Deep vein thrombosis in stroke: the use of plasma D-dimer level as a screening test in the rehabilitation setting. Stroke 1996;27:1516-1520
63. Kelly J, Rudd A, Lewis RR, Hunt BJ. Venous thromboembolism after acute stroke. Stroke 2001;32:262-267
64. Kelly J, Rudd A, Lewis RR, et al. Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers. J Thromb Haemost 2004;2:1321-1326